Abbotsford, Canada Clinical Trials

A listing of Abbotsford, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction <2% receives enzalutamide, and ctDNA fraction 2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post …

gonadotropin releasing hormone
testosterone
ct scan
prostate adenocarcinoma
enzalutamide
BC Cancer - Abbotsford Centre
 (1.0 away) Contact site
  • 0 views
  • 30 May, 2021
  • +4 other locations
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Summit is developing ridinilazole as a novel antimicrobial for Clostridioides difficile Infection (CDI), formerly known as Clostridium difficile Infection, with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these …

clostridium difficile
antibiotics
vancomycin
antibiotic therapy
diarrhea
Mission Hill Medical Clinic
 (5.8 away) Contact site
  • 101 views
  • 16 Apr, 2021
  • +257 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is nave to BCG treatment (Cohort B). The primary hypothesis …

Exdeo Clinical Research Inc. ( Site 0165)
 (0.7 away) Contact site
  • 108 views
  • 25 Jul, 2021
  • +138 other locations
The Effect of Higher Protein Dosing in Critically Ill Patients

The investigator will investigate the effects of higher protein/amino acid dosing (2.2 g/kg/d) vs usual protein/amino acid dosing (1.2 g/kg/d) on clinical outcomes in nutritionally high risk ill patients.

amino acids
severe malnutrition
sarcopenia
Surrey Memorial Hospital
 (25.7 away) Contact site
  • 121 views
  • 02 Jul, 2021
  • +93 other locations
A Study of Apalutamide in Participants With High-Risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and …

adenocarcinoma
apalutamide
antiandrogen therapy
adenocarcinoma of prostate
androgen suppression
Exdeo Clinical Research Inc
 (0.9 away) Contact site
  • 291 views
  • 25 Jul, 2021
  • +353 other locations
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.

invasive bladder cancer
radical cystectomy
gemcitabine
conjugated bilirubin
neutrophil count
Exdeo Clinical Research Inc
 (0.9 away) Contact site
  • 0 views
  • 25 Jul, 2021
  • +312 other locations
A Study of TAR-200 in Combination With Cetrelimab TAR-200 Alone or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease.

invasive bladder cancer
intravesical bcg
cystoscopy
carcinoma in situ
radical cystectomy
Exdeo Clinical Research Inc
 (0.9 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +176 other locations
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

The purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.

Exdeo Clinical Research Inc.
 (0.7 away) Contact site
  • 0 views
  • 06 Jul, 2021
  • +143 other locations
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming …

aromatase inhibitor
sentinel lymph node biopsy
endocrine therapy
erbb2
metastasis
BCCA-Abbotsford Cancer Centre
 (1.0 away) Contact site
  • 591 views
  • 25 Jul, 2021
  • +318 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab (MK-3475) and lenvatinib (E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), biliary tract cancers (BTC), or pancreatic cancer.

measurable disease
steroid therapy
solid tumour
combined modality therapy
epidermal growth factor
BC Cancer - Abbotsford ( Site 0200)
 (1.0 away) Contact site
  • 611 views
  • 25 Jul, 2021
  • +88 other locations